Real-World Data Linkage Research Platform
This study aims to address the lack of intelligent governance tools in clinical data management to promote efficient governance and secure sharing of real-world health data. To achieve this, a self-adaptive, automated governance intelligent agent will be developed based on a High-Order Programming (HOP) architecture, integrating Large Language Models (LLMs) and deep learning techniques. The agent will continuously monitor and correct data quality issues in real time, improving data accuracy and usability.
In parallel, the project will establish a trusted data-sharing framework by integrating AI Confidential Computing (AICC) with Trusted Data Matrix (TDM) technologies. This framework will enable secure, real-time cross-institutional data exchange and collaborative computation while protecting sensitive information.
Overall, the study aims to transform fragmented clinical data into high-quality, standardized, and securely accessible resources, thereby facilitating the circulation of data value and advancing collaborative medical research.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This multicenter, observational cohort study aims to integrate longitudinal health data from China, including routine health examinations, electronic medical records, and disease registries. The platform is designed to address key data challenges in the medical domain, particularly in chronic diseases and suboptimal health status. It is driven by two primary objectives:
- Intelligent and automated data governance To ensure high data quality, the platform will engineer a self-adaptive, automated governance intelligent agent. Integrating Large Language Models (LLMs) and High-Order Programming (HOP), this agent actively monitors and corrects real-world data issues, such as missing values, redundancies, and formatting inconsistencies. Through deep learning, the agent continuously optimizes its governance rules to adapt to complex medical data environments.
- Trusted and secure data sharing To facilitate multicenter collaborative research, the study will establish a secure and trusted data-sharing framework. By integrating AI confidential computation (AICC) with Trusted Data Matrix (TDM) technologies, the platform provides hardware-level security guarantees. This ensures that real-time, cross-institutional data exchange and collaborative computation without exposing sensitive patient information.
Overall Objective The platform aims to transform heterogeneous clinical data into standardized, high-quality, and securely accessible resources, thereby enabling efficient data utilization and promoting the value circulation of medical data for real-world evidence research.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Yuanyuan Kong, PhD
- Puhelinnumero: +86 1063139362 +86 15810026760
- Sähköposti: kongyy@ccmu.edu.cn
Tutki yhteystietojen varmuuskopiointi
- Nimi: Hao Wang, PhD
- Puhelinnumero: +86 1063139363 +86 18301250922
- Sähköposti: hao.wang@mail.ccmu.edu.cn
Opiskelupaikat
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 100050
- Beijing Friendship Hospital, Capital Medical University.No. 95, Yongan Road, Xicheng District, Beijing, 100050, China
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
This study establishes a multicenter, observational real-world data platform integrating longitudinal health data from multiple sources across China, including routine health examinations, electronic medical records, and disease registries. The platform is designed to support population-level research without restriction to specific diseases or conditions, enabling inclusive and continuous assessment of health status, disease risk, progression, and outcomes in real-world settings.
All available individuals with usable health-related data are eligible for inclusion, with minimal restrictions to maximize data coverage and representativeness. Both retrospective and prospective data will be incorporated and linked at the individual level using standardized protocols within a secure data governance and privacy protection framework.
Kuvaus
Inclusion Criteria:
Participants will be eligible for inclusion if they meet all of the following criteria:
- Availability of any health-related data generated from routine clinical care, health examinations, or disease surveillance systems, regardless of disease type or health status.
- Presence of at least one type of usable data, including but not limited to diagnostic information (structured or unstructured), laboratory results, imaging data, or basic demographic information.
- Records contain sufficient information (appropriately anonymized) to allow data organization and, where feasible, linkage at the individual level across time points or data sources.
Exclusion Criteria:
Participants or records meeting any of the following criteria will be excluded:
- Records lacking minimal essential information required to distinguish individual records or support basic analysis (e.g., completely missing identifiers or time information).
- Records confirmed to be invalid, including system-generated test data, corrupted entries, or records that do not represent real clinical or health-related events.
- Exact duplicate records that cannot be resolved through standard data processing (only one record will be retained when duplicates are identifiable).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Data-Link Cohort
The study cohort is derived from a multicenter, population-based real-world data platform that integrates longitudinal data from electronic medical records, disease registries, and routine health examinations across multiple institutions.
The platform is designed to support broad, disease-agnostic research and enable dynamic evaluation of health status, disease risk, and outcomes in real-world settings.
|
This is an observational study.
No intervention will be applied.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Accuracy Rate of Automated Data Governance
Aikaikkuna: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data accuracy will be evaluated by measuring the proportion of data values that correctly match the gold-standard reference after automated data governance.
The accuracy rate will be calculated as the percentage of correctly recorded or corrected data elements among all evaluated data elements.
Values range from 0% to 100%, with higher values indicating better data accuracy.
|
2026.5.30 to 2028.12.31
|
|
Completeness Rate of Automated Data Governance
Aikaikkuna: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in improving data completeness will be evaluated by measuring the proportion of required data fields that are complete after automated data governance.
The completeness rate will be calculated as the percentage of non-missing required data elements among all required data elements.
Values range from 0% to 100%, with higher values indicating better data completeness.
|
2026.5.30 to 2028.12.31
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Correction Accuracy of Automated Data Governance
Aikaikkuna: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in resolving identified data quality issues will be evaluated by measuring correction accuracy.
Correction accuracy will be calculated as the percentage of identified data quality issues (e.g., missing values, format inconsistencies, and logical conflicts) that are correctly resolved after automated data governance, compared with the gold-standard reference dataset.
Values range from 0% to 100%, with higher values indicating better correction performance.
|
2026.5.30 to 2028.12.31
|
|
Data Standardization Rate of Automated Data Governance
Aikaikkuna: 2026.5.30 to 2028.12.31
|
Using a manually curated gold-standard dataset, the effectiveness of the intelligent agent in standardizing data will be evaluated by measuring the proportion of data elements that conform to predefined data standards, terminologies, and formatting rules after automated data governance.
The data standardization rate will be calculated as the percentage of evaluated data elements that meet standardized data specifications among all assessed data elements.
Values range from 0% to 100%, with higher values indicating better data standardization.
|
2026.5.30 to 2028.12.31
|
|
Cross-institutional Data Usability of Automated Data Governance
Aikaikkuna: 2026.5.30 to 2028.12.31
|
Using datasets derived from participating institutions, the effectiveness of the intelligent agent in improving cross-institutional data usability will be evaluated by measuring the proportion of governed datasets that can be successfully integrated, interpreted, and used across different institutions according to predefined interoperability and usability criteria after automated data governance.
Cross-institutional data usability will be calculated as the percentage of datasets meeting prespecified usability criteria among all evaluated datasets.
Values range from 0% to 100%, with higher values indicating better cross-institutional usability.
|
2026.5.30 to 2028.12.31
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Yuanyuan Kong, Beijing Friendship Hospital
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- D. Reddy, "Data Engineering Challenges in AI automation," 2023 International Conference on Computing, Electronics & Communications Engineering (iCCECE), Swansea, United Kingdom, 2023, pp. 107-112
- Penberthy LT, Rivera DR, Lund JL, Bruno MA, Meyer AM. An overview of real-world data sources for oncology and considerations for research. CA Cancer J Clin. 2022 May;72(3):287-300. doi: 10.3322/caac.21714. Epub 2021 Dec 29.
- Kam K.H. Ng, Chun-Hsien Chen, C.K.M. Lee, Jianxin (Roger) Jiao, Zhi-Xin Yang; A systematic literature review on intelligent automation: Aligning concepts from theory, practice, and future perspectives; Advanced Engineering Informatics; 2021 January; Volume 47; 101246
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- Data-Link
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Krooniset sairaudet
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrytointiRefractory Chronic Graft versus Host Disease (cGVHD)Belgia
-
Novartis PharmaceuticalsRekrytointiKrooninen myelooinen leukemia | Leukemia, Myelogenous, Chronic, Philadelphia Chromosome PositiveKanada, Australia, Etelä -Korea
-
Ascentage Pharma Group Inc.Ei vielä rekrytointiaRelapsoituneet/refraktoriset hematologiset pahanlaatuiset kasvaimet | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL | Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation) | Relapsi- tai refraktori-mantelisolulymfooma... ja muut ehdotKiina, Yhdysvallat